Research
NEN RADAR Survey Launch Help SPARC-Europe Enhance NEN Cancer Care
What is the NEN RADAR Survey?
Peptide receptor radionuclide therapy (PRRT), also known as radioligand therapy (RLT), can be a life-saving treatment for neuroendocrine neoplasm (NEN) cancer patients. However, many patients and healthcare professionals face significant challenges in accessing and understanding this treatment. SPARC-Europe has launched the NEN Radioligand Awareness Research (NEN RADAR) to explore these challenges across Europe. The survey findings will inform evidence-based policy recommendations aimed at improving awareness, access, and availability of PRRT.
Who should participate?
We invite NEN cancer patients and healthcare professionals involved in their care to participate in this important survey.
Do you know someone who fits this description? Please share the survey with them and help spread the word.
Make a difference in the future of NEN cancer care! Click below to take the survey now.
Patient
Healthcare Professional
www.neuroendocrinecancer.org.uk
Made with FlippingBook - Online magazine maker